proactive21 Jun 2021 18:07
In the update, the company said it has begun additional pre-clinical studies on NXP002, its inhaled treatment for idiopathic pulmonary fibrosis, with the aim of creating a more robust data package.
The ultimate goal is to increase the value of this asset, a repurposed form of a product called tranilast, “rendering it more attractive to licensing partners”.